Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Atopic Dermatitis
Clinical trial register · United States · industry-sponsored

Atopic Dermatitis Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 41 Florida 33 Alabama 18 Georgia 18 Illinois 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer8 AbbVie5 Incyte Corporation3 Apogee Therapeutics, Inc.2 Target PharmaSolutions, Inc.2
State
California41 Florida33 Alabama18 Georgia18 Illinois18
All 35 states
Target enrolment
to

Atopic Dermatitis trials in the USA

51 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Observational Study of Patients With Dermatologic Disease
NCT07748169Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Target PharmaSolutions, Inc.
Observational
2,000,000
New York
2026-09
Recruiting
Pfizer
Phase 3
1,375
Arizona, California, Georgia, Indiana, Michigan, Oklahoma, Pennsylvania, Tennessee
2026-08-24
Recruiting
Pfizer
Phase 3
375
Alabama, Arizona, California, Florida, Georgia, North Dakota, Texas
2026-08-17
Recruiting
Integrative Skin Science and Research
Phase 4
40
California
2026-07-21
Active, closed
Rejuvaskin
Not applicable
35
Nevada
2026-07-06
Recruiting
Enveda Therapeutics
Phase 2
200
California, Florida, Indiana, Texas
2026-06-29
By invitation
Inmagene LLC
Phase 2
400
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2026-06-05
Recruiting
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 1
144
Alabama, Arkansas, California, Florida, South Carolina, Texas
2026-05-22
Recruiting
Pfizer
Observational
150
California
2026-04-24
Recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
DrugSoquelitinib
Corvus Pharmaceuticals, Inc.
Phase 2
200
California
2026-02
Recruiting
Hoffmann-La Roche
Phase 2
120
California, Florida, Georgia, Michigan, Minnesota, Pennsylvania
2026-01-08
Active, closed
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
Pfizer
Phase 3
450
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Michigan, New York, North Dakota
2025-11-24
Recruiting
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Ohio, Pennsylvania
2025-11-20
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Active, closed
Novartis Pharmaceuticals
Phase 2
34
California, Maryland, New Jersey
2025-11-10
Active, closed
Triveni Bio
Phase 2
95
California, Florida, Indiana, Pennsylvania, Texas, Washington
2025-08-26
Recruiting
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Recruiting
Turn Therapeutics
Phase 2/3
190
Texas
2025-07-11
Active, closed
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Recruiting
Inmagene LLC
Phase 2
405
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2025-06-17
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Active, closed
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
Bambusa Therapeutics
Phase 1
237
California, New York
2025-02-27
Not yet open
Power Life Sciences Inc.
Observational
500
California
2025-01
Active, closed
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Active, closed
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Recruiting
Pfizer
Phase 1
119
California, Florida, Michigan, Pennsylvania
2024-11-05
Active, closed
AbbVie
Phase 3
699
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Recruiting
AbbVie
Phase 2
60
California, Michigan
2024-08-14
Recruiting
Oneness Biotech Co., Ltd.
Phase 2
114
California, Texas
2024-08-08
Active, closed
AbbVie
Phase 3
184
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Recruiting
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-04-29
Recruiting
Incyte Corporation
Observational
958
North Carolina
2023-09-13
Recruiting
Pfizer
Phase 2
340
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2023-08-22
Recruiting
Pfizer
Observational
400
New York
2023-07-25
Recruiting
Brexogen Inc.
Phase 1
45
Arkansas, Pennsylvania
2023-04-18
Recruiting
Incyte Corporation
Observational
5,621
North Carolina
2023-03-27
By invitation
Eli Lilly and Company
Phase 3
333
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Active, closed
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
Q32 Bio Inc.
Phase 2
102
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Maryland
2022-09-30
Active, closed
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
Target PharmaSolutions, Inc.
Observational
15,000
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2018-12-21
Active, closed
AbbVie
Phase 3
1,533
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2018-08-09
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2015-10-15
Active, closed
Bausch Health Americas, Inc.
Observational
8,000
Pennsylvania
2005-06-27
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/atopic-dermatitis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 19 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies listing the condition Atopic Dermatitis.

How many Atopic Dermatitis trials are recruiting in the US?

28 of the 51 studies on this page are recruiting new participants as of the 19 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 19 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Atopic Dermatitis), 51 studies
PhaseStudiesRecruitingShare
Phase 2221143.1%
Observational11721.6%
Phase 311421.6%
Phase 1447.8%
Not applicable102%
Phase 2/3112%
Phase 4112%

Most active sponsors

Lead sponsors with the most studies (Atopic Dermatitis)
Lead sponsorStudiesRecruiting
Pfizer88
AbbVie51
Incyte Corporation32
Apogee Therapeutics, Inc.21
Eli Lilly and Company20
Hoffmann-La Roche21
Inmagene LLC21
Novartis Pharmaceuticals21
Regeneron Pharmaceuticals21
Target PharmaSolutions, Inc.20

Top states

Top states (Atopic Dermatitis), by number of studies with a site there
StateStudies
California41
Florida33
Alabama18
Georgia18
Illinois18
Arizona17
Arkansas13
Indiana13
Michigan13
Idaho11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.